Tucson, AZ
Ketamine Therapy clinics in Tucson
Tucson has multiple clinics offering ketamine therapy, a fast growing segment for treatment resistant depression, PTSD, chronic pain, and anxiety. Arizona has a growing ketamine clinic market; the state board requires continuous monitoring during infusions. Most Tucson clinics deliver IV ketamine infusions in a monitored clinical setting, typically across a 6 session induction protocol, followed by maintenance infusions. Spravato (esketamine), the FDA approved nasal spray for treatment resistant depression, is available in Tucson only at REMS certified clinics and is often covered by insurance when medical necessity is documented. Compounded ketamine lozenges and troches are also prescribed in Tucson, sometimes through telehealth platforms like Mindbloom, Joyous, and Innerwell, subject to Ryan Haight Act and DEA special registration considerations. Local pricing in Tucson sits in the affordable range: single IV infusions run 400 to 700 dollars, a full 6 session protocol lands at 2,400 to 4,200, and Spravato copays depend on insurance coverage. A reputable Tucson ketamine clinic will pair pharmacology with integration support, monitor vitals during infusion, and have a clear crisis and follow up plan.
MD on staff
Integrative Recovery Medicine
- IV Therapy
- Ketamine Therapy
- Chelation Therapy
- Psychedelic Therapy
- Peptide Therapy
Drip Medical Care
- NAD IV Therapy
- Vitamin IV Therapy
- IV Therapy
- Laser Therapy (LLLT)
- IV Hydration
Calm Clinic
- Transcranial Magnetic Stimulation (TMS)
- Ketamine Therapy
- Psychedelic Therapy
Desert Sage Behavioral Health
- Transcranial Magnetic Stimulation (TMS)
- Ketamine Therapy
- Psychedelic Therapy
Regulatory context
A note on Arizona's ketamine therapy rules.
Ketamine is a DEA Schedule III controlled substance, FDA-approved as a dissociative anesthetic and used off-label for treatment-resistant depression, PTSD, and chronic pain. The FDA approved esketamine (Spravato) in 2019 for treatment-resistant depression under a Risk Evaluation and Mitigation Strategy (REMS) program that requires in-office administration at certified sites. MDMA-assisted therapy remains Schedule I; the FDA issued a Complete Response Letter in August 2024 to Lykos Therapeutics on its MDMA new drug application. Psilocybin is Schedule I and holds FDA Breakthrough Therapy designation through sponsors such as Compass Pathways and Usona, but has not received FDA approval. Oregon Measure 109 (passed 2020, operational 2023) created a state psilocybin service center framework, and Colorado Proposition 122 (2022) authorized regulated healing centers.
-
Arizona Psilocybin Research Grant (SB 1726, 2023)
Allocated $5 million for whole-mushroom psilocybin clinical research; does not create a therapeutic access framework. -
Arizona Controlled Substances Act
Mirrors federal scheduling outside the research grant program.
Arizona enforces federal DEA scheduling and has not decriminalized psilocybin or MDMA. The Arizona Medical Board and Arizona Board of Osteopathic Examiners oversee prescribing conduct. DEA enforcement on ketamine clinics focuses on compounding sources, diversion, and billing fraud. Ryan Haight Act rules apply to telehealth ketamine prescriptions, with DEA flexibilities extended through 2025.